Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 701-704

  Kuo, Chien Neng ^a,b   Chen, Chung Yi ^c   Lai, Chien Hsiung ^a,b   Lai, Li Ju ^a,b   Wu, Pei Chen ^a,b   Hung, Chia Hui ^a,b   Chen, Ching Hsein ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Age related macular degeneration; Bevacizumab; Cell cycle; G1 S arrest; Human retinal pigment epithelial cells

Indexed keywords

BEVACIZUMAB; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; DNA; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA SYNTHESIS; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PIGMENT EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL SURVIVAL; CELLS, CULTURED; CYCLIN D; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MACULAR DEGENERATION; PHOSPHORYLATION; RETINAL PIGMENT EPITHELIUM; RETINOBLASTOMA PROTEIN; S PHASE CELL CYCLE CHECKPOINTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865189663     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.986     Document Type: Article

References (19)

1. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J, Seigel GM, Neekhra A, Gramajo AL, Brown DJ, et al: Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26: 512-518, 2006. (Pubitemid 44620391)
2. Garg S, Brod R, Kim D, Lane RG, Maguire J and Fischer D: Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 36: 252-256, 2008. (Pubitemid 351560274)
3. Forooghian F, Cukras C and Chew EY: Retinal angiomatous proliferation complicated by pigment epithelial tear following intravitreal bevacizumab treatment. Can J Ophthalmol 43: 246-248, 2008. (Pubitemid 351518187)
4. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S and Tano Y: Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86: 372-376, 2008.
5. Arias L, Caminal JM, Rubio M, Pujol O and Arruga J: Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol 17: 992-995, 2007. (Pubitemid 351262915)
6. Subramanyam A, Phatak S and Chudgar D: Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment. Indian J Ophthalmol 55: 483-486, 2007.
7. Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P; Tuebingen Bevacizumab Study Group: Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90: 1316-1321, 2006. (Pubitemid 44621499)
8. Brar VS, Sharma RK, Murthy RK and Chalam KV: Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells. J Ocul Pharmacol Ther 25: 507-511, 2009.
9. Attar-Schneider O, Drucker L, Zismanov V, Tartakover- Matalon S, Rashid G and Lishner M: Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest 92: 178-190, 2012.
10. Mueller A, Odze R, Jenkins TD, Shahsesfaei A, Nakagawa H, Inomoto T and Rustgi AK: A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res 57: 5542-5549, 1997. (Pubitemid 28006762)
11. Yoo YA, Kim MJ, Park JK, Young Min Chung, Jong HL, Sung-Gil C, Jun SK, and Young DY: Mitochondrial ribosomal protein L41 suppresses cell growth in association with p53 and p27Kip1. Mol Cell Biol 25: 6603-6616, 2005. (Pubitemid 41023234)
12. Masamha CP and Benbrook DM: Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69: 6565-6572, 2009.
13. Yu Q, Geng Y and Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021, 2001. (Pubitemid 32612319)
14. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclindependent kinases. Genes Dev 9: 1149-1163, 1995.
15. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
16. Vivar OI, Lin C, Firestone GL and Bjeldanes LF: 3,3′- Diindolylmethane induces a G1 arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol 78: 469-476, 2009.
17. Jinno S, Hung SC and Okayama H: Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4. Oncogene 18: 565-571, 1999. (Pubitemid 29080313)
18. Das SK, Hashimoto T and Kanazawa K: Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim Biophys Acta 1780: 743-749, 2008.
19. Ukomadu C and Dutta A: p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 278: 43586-43594, 2003. (Pubitemid 37345984)